BETTER MEDICINE
FOR ALL

MedinCell is a pharmaceutical company at commercial stage. We develop a portfolio of long-acting injectables in various therapeutic areas. Our proprietary technology BEPO® aims to ensure patient compliance, improve the effectiveness and accessibility of treatments, and reduce their environmental footprint. We collaborate with tier-one pharmaceutical companies and foundations to improve Global Health through new therapeutic options.

Latest news

Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favorable characteristics of an extended-release profile 

Read press release

Session en français

Rendez-vous le mardi 2 mai à 18h30 pour une vidéoconférence dédiée à l'approbation de UZEDY™

English session

On Tuesday, May 2 at 7.30 pm (CEST) participate in our videoconference dedicated to the approval of UZEDY™

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.